Semaglutide and walking capacity in people with symptomatic peripheral artery disease and T2 diabetes

1. What was the aim of the STRIDE trial?

2. What type of trial was STRIDE?

3. Which patients were eligible for the STRIDE trial?

4. What treatment was participants randomly assigned to receive?

5. What was the primary endpoint of the STRIDE trial?

6. What effect did semaglutide have on maximum walking distance?

7. What was the median improvement in maximum walking distance with semaglutide compared with placebo?

8. Which symptoms improved with semaglutide?

9. What was the mean net decrease in weight with semaglutide versus placebo?

10. What was the conclusion of the STRIDE trial?